Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Hematology"
DOI: 10.1002/ajh.24954
Abstract: Experience with intensive chemotherapy for relapsed/refractory multiple myeloma (RRMM) using VDT PACE regimen and its modifications (VDT PACE‐like regimens: VPLRs) outside TOTAL THERAPY trials is limited. We analyzed the outcomes of 141 patients with RRMM… read more here.
Keywords: relapsed refractory; refractory multiple; myeloma; vdt pace ... See more keywords
Lung function impairment in pediatric patients with sickle cell anemia from Nigeria is associated with low steady state hemoglobin
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25373
Abstract: 1. NCCN. Multiple Myeloma (Version 3.2017); 2016. https://www.nccn. org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed February 15, 2017. 2. Carlson JJ, Guzauskas GF, Chapman RH, et al. Cost-effectiveness of drugs to treat relapsed/refractory multiple myeloma in the United States. J… read more here.
Keywords: relapsed refractory; refractory multiple; myeloma; multiple myeloma ... See more keywords
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2018 at "Cancer"
DOI: 10.1002/cncr.31706
Abstract: Daratumumab is a human CD38‐directed monoclonal antibody indicated for the treatment of relapsed and refractory multiple myeloma (MM). read more here.
Keywords: relapsed refractory; refractory multiple; treatment; multiple myeloma ... See more keywords
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34756
Abstract: Teclistamab, a B‐cell maturation antigen × CD3 bispecific antibody, demonstrated an overall response rate of 63.0% in 165 heavily pretreated patients with relapsed or refractory multiple myeloma in the phase 1/2 MajesTEC‐1 study. Cytokine release… read more here.
Keywords: relapsed refractory; refractory multiple; patients relapsed; multiple myeloma ... See more keywords
Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results
Sign Up to like & getrecommendations! Published in 2022 at "Hematological Oncology"
DOI: 10.1002/hon.3012
Abstract: Therapeutic strategies that target novel pathways are urgently needed for patients with relapsed/refractory multiple myeloma (RRMM). Ibrutinib is an oral covalent inhibitor of Bruton tyrosine kinase, which is overexpressed in MM cells. This phase 1… read more here.
Keywords: relapsed refractory; refractory multiple; patients relapsed; lenalidomide dexamethasone ... See more keywords
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials
Sign Up to like & getrecommendations! Published in 2022 at "Hematological Oncology"
DOI: 10.1002/hon.3031
Abstract: The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT‐2 trial, leading to its approval in relapsed/refractory multiple myeloma (RRMM). The present study… read more here.
Keywords: relapsed refractory; refractory multiple; lenalidomide dexamethasone; multiple myeloma ... See more keywords
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Hematology"
DOI: 10.1007/s00277-019-03739-2
Abstract: The randomized phase III ADMYRE trial evaluated plitidepsin plus dexamethasone (DXM) versus DXM alone in patients with relapsed/refractory multiple myeloma after at least three but not more than six prior regimens, including at least bortezomib… read more here.
Keywords: relapsed refractory; refractory multiple; months arm; multiple myeloma ... See more keywords
De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis
Sign Up to like & getrecommendations! Published in 2025 at "Annals of Hematology"
DOI: 10.1007/s00277-025-06529-1
Abstract: Teclistamab, a BCMA×CD3 bispecific antibody, demonstrates high efficacy in relapsed/refractory multiple myeloma (RRMM). However, optimal dosing strategies outside clinical trials remain undefined. Thus, we performed a retrospective, multicentre analysis of 73 RRMM patients treated with… read more here.
Keywords: multiple myeloma; refractory multiple; dosing; relapsed refractory ... See more keywords
Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077)
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-017-2504-5
Abstract: IntroductionWhile lenalidomide monotherapy is established for relapsed and/or refractory multiple myeloma (MM) treatment, combination therapies including lenalidomide are still under investigation in a number of phase 2/3 studies. In the current study, a treatment regime… read more here.
Keywords: relapsed refractory; combination; refractory multiple; bendamustine prednisolone ... See more keywords
Target trial emulation of carfilzomib safety among patients with relapsed/refractory multiple myeloma using a nationwide observational data in Korea
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-024-05800-8
Abstract: Carfilzomib, commonly used for relapsed/refractory multiple myeloma (RRMM), has been associated with various adverse events in randomized controlled trials (RCTs). However, real-world safety data for a more diverse population are needed, as carfilzomib received expedited… read more here.
Keywords: adverse events; trial; refractory multiple; carfilzomib ... See more keywords
Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2022 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-022-06979-7
Abstract: This study aimed to better understand the patient perspective and treatment experience of relapsed and/or refractory multiple myeloma (RRMM). This qualitative study enrolled adult RRMM patients from 6 US clinics who had ≥ 3 months of life… read more here.
Keywords: treatment experience; relapsed refractory; treatment; multiple myeloma ... See more keywords